Acute-phase proteins and hematologic values in ovine lentivirus-infected lambs treated with recombinant ovine IFN-tau.
To evaluate changes in complete blood cell (CBC) counts, haptoglobin and fibrinogen in ovine lentivirus (OvLV)-infected lambs treated with recombinant ovine interferon-tau (rOVIFN-tau), 24 lambs were allocated to one of four groups (n = 6 per group): (1) virus + rOvIFN-tau, VI, (2) virus + placebo, VP, (3) no virus + rOVIFN-tau, NVI, and (4) no virus + placebo, NVP. Three lambs in each group were treated once a day for 12 weeks, and the remaining 3 lambs were treated for 33 weeks. Blood was collected at days 0, 7, and 10 and at weeks 2-10, 12, 32, and 33 to determine CBC counts, as well as haptoglobin and fibrinogen levels. Hematologic values remained within normal limits in all groups. However, hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), and packed cell volume (PCV) values decreased (p < 0.05) in the two rOvIFN-tau-treated groups (VI and NVI) compared with the placebo-treated (VP and NVP) groups. Both rOvIFN-upsilon and OvLV had a mild negative effect on neutrophil numbers. Although Hb, MCV, MCHC, PCV, and neutrophil values declined in the rOvIFN-tau-treated lambs compared with the placebo-treated lambs, these values remained within the reference range for sheep. Experimental lambs did not show adverse clinical signs associated with OvLV infection or as a result of rOvIFN-tau treatment. The lack of significant side effects of high-dose rOvIFN-tau in sheep and previous reports of broad-spectrum and cross-species antiviral activity suggest that rOvIFN-tau warrants further investigation as an antiviral therapeutic agent.
de la Concha-Bermejillo
A
A
Department of Veterinary Pathobiology, Texas A&M University Agricultural Experiment Station, San Angelo 76901, USA. adelaconcha@cvm.tamu.edu
Singh
B
B
Whitney
M S
MS
Bazer
F W
FW
D000209:Acute-Phase Proteins / Q000032:analysis*; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001772:Blood Cell Count; D004909:Erythrocyte Indices; D005340:Fibrinogen / Q000032:analysis; D006242:Haptoglobins / Q000032:analysis; D007370:Interferon Type I / Q000494:pharmacology / Q000627:therapeutic use*; D016180:Lentivirus Infections / Q000097:blood* / Q000628:therapy; D008297:Male; D011021:Pneumonia, Progressive Interstitial, of Sheep / Q000097:blood / Q000628:therapy*; D011257:Pregnancy Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012756:Sheep / Q000097:blood* / Q000821:virology; D016037:Single-Blind Method
D000209:Acute-Phase Proteins; D000998:Antiviral Agents; D006242:Haptoglobins; D007370:Interferon Type I; D011257:Pregnancy Proteins; D011994:Recombinant Proteins; C020947:interferon tau; D005340:Fibrinogen